Jean-Francois Korobelnik

Participe à 2 sessions

Sessions auxquelles Jean-Francois Korobelnik participe

Vendredi 20 Juin, 2025

Fuseau horaire: (GMT-05:00) Eastern Time (US & Canada)

12:10

A 96-week PULSAR Phase 3 trial post-hoc analysis: Rapid and sustained fluid control with aflibercept 8mg every 12 weeks or longer, as defined by fluid-free status at Weeks 16, 48, and 96 stratified by baseline CRT and BCVA - 5434

Vancouver Convention Centre (Édifice Est) - Ballroom B

12:11 - 12:16 | 5 minutes

Author’s Name(s): David Wong, Praveen Patel, Paolo Lanzetta, Jean-François Korobelnik, Sobha Sivaprasad, Sergio Leal, Tobias Machewitz, Xin ZhangAuthor’s Disclosure Block: David Wong: Alcon, Employment/honoraria/consulting fees, Abbviw, Employment/honoraria/consulting fees, Apellis, Employment/honoraria/consulting fees, Astellas, Employment/honoraria/consulting fees, Bayer, Grant/research support, Roche, Employment/honoraria/consulting fees, Zeiss, Emp...

12:15

Q&A

Vancouver Convention Centre (Édifice Est) - Ballroom B

12:16 - 12:19 | 3 minutes